» Articles » PMID: 29554386

Appointment Compliance in Patients With Diabetic Macular Edema and Exudative Macular Degeneration

Overview
Date 2018 Mar 20
PMID 29554386
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: The purpose of this study is to compare cancellation and no-show rates in patients with diabetic macular edema (DME) and exudative macular degeneration (wet AMD).

Patients And Methods: An anonymous survey was sent to 1,726 retina specialists inquiring as to the number of appointments their patients with DME and wet AMD attended, cancelled, or did not show up for in 2014 and 2015.

Results: Data were obtained on 109,599 appointments. Patients with DME in the U.S. had a 1.591-times increased odds of cancelling or no-showing to their appointments than patients with wet AMD (P < .0001). Patients with DME in Europe had a 1.918-times increased odds of cancelling or no showing to their appointments than patients with wet AMD (P < .0001).

Conclusion: Patients with DME in the U.S. and Europe cancelled and no-showed to their appointments significantly more often than patients with wet AMD. These findings can be taken into consideration when establishing treatment plans for patients with DME. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:186-190.].

Citing Articles

Predictors of Vision Loss After Lapse in Antivascular Endothelial Growth Factor Treatment in Patients With Diabetic Macular Edema.

Chalasani M, Maatouk C, Markle J, Singh R, Talcott K J Vitreoretin Dis. 2024; :24741264241305123.

PMID: 39678936 PMC: 11645682. DOI: 10.1177/24741264241305123.


Anti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology.

Nakao S, Kusuhara S, Murakami T Graefes Arch Clin Exp Ophthalmol. 2024; 262(12):3749-3759.

PMID: 38995350 PMC: 11608304. DOI: 10.1007/s00417-024-06558-y.


Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema.

Rubsam A, Hossl L, Rau S, Boker A, Zeitz O, Joussen A J Clin Med. 2024; 13(6).

PMID: 38542043 PMC: 10970839. DOI: 10.3390/jcm13061819.


Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab.

Garweg J, Steinhauer S J Clin Med. 2024; 13(6).

PMID: 38541760 PMC: 10971211. DOI: 10.3390/jcm13061534.


Intravitreal DEX Implant for the Treatment of Diabetic Macular Edema: A Review of National Consensus.

Spinetta R, Petrillo F, Reibaldi M, Tortori A, Mazzoni M, Metrangolo C Pharmaceutics. 2023; 15(10).

PMID: 37896220 PMC: 10610055. DOI: 10.3390/pharmaceutics15102461.